1.Status Quo of Chronic Liver Diseases, Including Hepatocellular Carcinoma, in Mongolia.
Amarsanaa JAZAG ; Natsagnyam PUNTSAGDULAM ; Jigjidsuren CHINBUREN
The Korean Journal of Internal Medicine 2012;27(2):121-127
Because Mongolia has much higher liver disease burden than any other regions of the world, it is necessary to provide information on real-time situation of chronic liver disease in Mongolia. In this article, we reviewed studies performed in Mongolia from 2000 to 2011 on seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among healthy individuals and patients with chronic liver diseases, and on the practice patterns for the management of liver cirrhosis and hepatocellular carcinoma (HCC). According to previous reports, the seroprevalence of HBV and HCV in general population in Mongolia is very high (11.8% and 15% for HBV and HCV, respectively). Liver cirrhosis is also highly prevalent, and mortality from liver cirrhosis remained high for the past decade (about 30 deaths per 100,000 populations per year). Among patients with cirrhosis, 40% and 39% are positive for HBsAg and anti-HCV, respectively, and 20% are positive for both. The seroprevalence is similar for HCC and more than 90% of HCC patients are positive for either HBV or HCV. The incidence of HCC in Mongolia is currently among the highest in the world. The mortality from HCC is also very high (52.2 deaths per 100,000 persons per year in 2010). Partly due to the lack of established surveillance systems, most cases of HCC are diagnosed at an advanced stage. The mortality from liver cirrhosis and HCC in Mongolia may be reduced by implementation of antiviral therapy program and control of alcohol consumption.
Carcinoma, Hepatocellular/blood/diagnosis/*epidemiology/mortality/therapy
;
Hepatitis B, Chronic/epidemiology
;
Hepatitis C, Chronic/epidemiology
;
Humans
;
Liver Cirrhosis/epidemiology
;
Liver Diseases/blood/diagnosis/*epidemiology/mortality/therapy
;
Liver Neoplasms/blood/diagnosis/*epidemiology/mortality/therapy
;
Mongolia/epidemiology
;
Prevalence
;
Prognosis
;
Risk Assessment
;
Risk Factors
;
Seroepidemiologic Studies
;
Time Factors
2.Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
Oidov BAATARKHUU ; Jae Seung LEE ; Jazag AMARSANAA ; Do Young KIM ; Sang Hoon AHN ; Nyamsuren NARANZUL ; Damba ENKHTUYA ; Nagir CHOIJAMTS ; Purev BATBAYAR ; Radnaa OTGONBAYAR ; Bat-Ulzii SARUUL ; Chuluunbaatar GANTUUL ; Baljinnyam GEGEEBADRAKH ; Narangerel TUVSHINBAYAR ; Dorjgotov BADAMSUREN ; Galsan ULZMAA ; Jamiyandorj OTGONBOLD ; Kwang-Hyub HAN
Clinical and Molecular Hepatology 2021;27(1):125-135
Background/Aims:
Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients.
Methods:
Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12).
Results:
Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×106 IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%).
Conclusions
LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries.